Evidence & regulatory context
- Mechanism
- Adenoviral gene-transfer construct expressing ANGPT1; no confident ChEMBL entity (gene therapy vector). CTgov keyword hits are trebananib / AMG 386, an Ang1-Ang2 neutralising peptibody with opposite pharmacology, plus ANG1/TIE2 biomarker studies; none is adenoviral Ang1 delivery, so n_trials=0 and flagged for manual review.
- Target
- Not recorded
- Injury models
- Endotoxin/LPS
- Reported indication
- Not recorded
- First approval
- Not recorded
- Development stage
- Not recorded
- ChEMBL record
- Not recorded
- ChEMBL max phase
- Not recorded
- Synonyms
- Not recorded
- Note
- Not recorded
Clinical trials 0
0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.
No linked human trial in this dataset.
Preclinical evidence 1
1 studies reported at therapy level; 1 evidence entries itemised.
MouseEndotoxin/LPSBALB/cMalen = 6 control mice per pretreatment groupintravenous24 h before LPS (pretreatment)
Model: intratracheal lipopolysaccharide acute lung injury
Adenoviral angiopoietin1 pretreatment reduced neutrophil infiltration and accelerated resolution of endotoxin-induced acute lung injury.
Extraction: extract · Supplied extraction confidence: 0.8. Machine-extracted fields require source verification.
